Deirisa Lopes Barreto

Deirisa Lopes Barreto

Auto-generated profile, based on publicly available information

Deirisa Lopes Barreto

Department of Rheumatology and Clinical Immunology, Maasstad hospital, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Verified
Journal Article
Closed access
PDF file
DSDenise E. Sampimon
Denise E. Sampimon
MKMario R. Korte
Mario R. Korte
DBDeirisa Lopes Barreto
Deirisa Lopes Barreto
AVAnniek Vlijm
Anniek Vlijm
RWRudy de Waart
Rudy de Waart
RKRaymond T. Krediet
Raymond T. Krediet
Objective: Encapsulating peritoneal sclerosis (EPS) is a severe complication of long-term peritoneal dialysis (PD). The aim of this study was to investigate whether dialysate levels of cancer antigen-125 (CA125), K+, interleukin (IL)-6, and vascular endothelial growth factor (VEGF) are early diagnostic markers of EPS. Therefore, we analyzed the time courses of the above described dialysate markers in EPS patients and controls. Methods: Dialysate and serum samples of 11 EPS patients and 31 control patients, all treated with PD for at least 57 months, were longitudinally collected during standard peritoneal permeability analyses. CA125 and IL-6 were measured in dialysate only, K+ and VEGF were measured in both dialysate and serum. CA125 and IL-6 are expressed as appearance rates (AR). The linear mixed model was used to analyze the time courses. Sensitivity and specificity were calculated based on the results of the last 2 time points. Results: No differences in the time courses of the different markers were present between the groups. For K+ and VEGF attributed to local production, no differences between the groups were found. However, AR-CA125 was lower during the last 3 years prior to EPS ( p < 0.05) and AR-IL-6 tended to be higher 2 years prior to EPS ( p = 0.09). The combination of AR-CA125 < 33 U/min and AR-IL-6 > 350 pg/min had a sensitivity of 70% and a specificity of 89% for the development of EPS. Conclusions: Compared to controls, AR-CA125 showed lower values and AR-IL-6 tended to be higher during the last years prior to the diagnosis of EPS. The sensitivity and specificity of the combination of CA125 and IL-6 indicate their potential use for an early diagnosis of EPS.

1 October 2013 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
DBDeirisa Lopes Barreto
Deirisa Lopes Barreto
RKRaymond T. Krediet
Raymond T. Krediet

1 May 2015 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
DBDeirisa Lopes Barreto
Deirisa Lopes Barreto
DSDirk G. Struijk
Dirk G. Struijk
RKRaymond T. Krediet
Raymond T. Krediet

1 September 2013 in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Verified
Journal Article
Open access
PDF file
DBDeirisa Lopes Barreto
Deirisa Lopes Barreto
ACAnnemieke M. Coester
Annemieke M. Coester
DSDirk G. Struijk
Dirk G. Struijk
RKRaymond T. Krediet
Raymond T. Krediet
♦ Background: Peritoneal effluent contains clinically relevant substances derived from intraperitoneal production or transperitoneal transport, or both. The glycoproteinase matrix metalloproteinase 2 (MMP-2) cleaves denatured collagen and complements other collagenases in the degradation of fibrillar collagens. Elevated intraperitoneal levels of plasminogen activator inhibitor 1 (PAI-1) have been demonstrated to be present in patients with intra-abdominal adhesions. The aim of the present study was therefore to investigate the potential for effluent MMP-2 and PAI-1 to be used as markers of the development of peritoneal alterations. In addition, MMP-2 was analyzed in previously frozen effluent samples from a uremic rat model, in which data concerning the severity of peritoneal fibrosis were available.

15 April 2011 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
DBDeirisa Lopes Barreto
Deirisa Lopes Barreto
ACAnnemieke M. Coester
Annemieke M. Coester
MNMarlies Noordzij
Marlies Noordzij
WSWatske Smit
Watske Smit
DSDirk G. Struijk
Dirk G. Struijk
RKRaymond T. Krediet
Raymond T. Krediet
Background. Cancer antigen (CA) 125 is a glycoprotein that provides data on the state of the peritoneal membrane in peritoneal dialysis (PD). Interleukin-6 (IL-6) acts as a mediator in acute-phase responses. The study evaluated the usefulness of CA125 and IL-6 in random effluent samples, by assessing their variability in individual patients during clinical practice at the outpatient department.

1 January 2019 in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Verified
Journal Article
Closed access
PDF file
DBDeirisa Lopes Barreto
Deirisa Lopes Barreto
DSDenise E. Sampimon
Denise E. Sampimon
DSDirk G. Struijk
Dirk G. Struijk
RKRaymond T. Krediet
Raymond T. Krediet
Background: No diagnostic tool or methodology is currently available for early detection of imminent encapsulating peritoneal sclerosis (EPS). The objective of this study was to investigate the predictive value of free water transport (FWT) and construct a panel of peritoneal effluent proteins for EPS alone or in combination with FWT. These parameters could be incorporated in the follow-up of peritoneal dialysis (PD) patients. Methods: A case-control study, nested in a longitudinal PD patient cohort, was conducted. Time-specific areas under the receiver operating characteristic (ROC) curve were calculated for FWT and effluent biomarkers at a lag time up to 3 years before EPS diagnosis. Free water transport was combined with appearance rates (AR) of biomarkers to assess their clinical validity. Results: Free water transport volume and AR of effluent bio-markers were investigated in 11 EPS patients and 34 long-term PD patients. Diagnostic performance was best for FWT (area under the curve [AUC] 0.94) followed by plasminogen activator inhibitor (PAI-1) AR. Throughout, diagnostic panels of FWT and AR of cancer antigen 125 (CA125), interleukin-6 (IL-6), or (PAI-1) yielded specificity estimates above 84%. The combination of FWT and PAI-1 AR identified the largest proportion of EPS patients at 1 year prior to diagnosis (sensitivity 100%, specificity 94%). Conclusion: Measurement of FWT is simple and has the highest predictive value for imminent EPS. The addition of effluent biomarkers provides an all-round insight into the state of the peritoneum. Our data indicate that combining FWT with either PAI-1, CA125, or IL-6 has the highest specificity. This is required to avoid unnecessary discontinuation of PD treatment.